Grants and Contributions

As part of the international consortium project “UK Biomanufacturing - 10143578 - NPmsDNA2024 - Development of in vivo targeted non-viral gene therapies”, this project's objective is to use Chromatin Bio's bioinformatics platform to design novel gene regulatory elements, improving gene expression in Mediphage therapeutic constructs for Stargardt disease, while reducing sequence complexity and increasing manufacturing yields.

Polestar will investigate the subpopulation of hemolyzed RBCs, hemoglobin gene-switching, and RBC anomalies, using state-of-the-art methods often applied for the first time to space samples.

The project will identify potential gene therapy targets that can confer radioprotective phenotypes by effectively reducing oxidative stress, DNA damage, and cell death responses whilst deepening our understanding of their underlying mechanisms.

This kit will be the first of its kind, integrating innovative upstream and downstream technologies that have been demonstrated to significantly enhance both upstream manufacturing yields and downstream processing recovery and contributing to the greater accessibility of ex-vivo gene therapy.

As part of the international consortium project "UK Multisector - BioM - MICRO-HTUO”, this project will focus on the validation of the AtomForge platform through the development of a novel treatment for Osteoporosis. The project will demonstrate the real world performance of the platform for use in drug discovery and optimization applications, while demonstrating a more rapid drug discovery method that couples the platform's experimental predictions with the UK partner's experimental methods.

This project will test hypotheses and experiment with new mechanisms to design a repeatable and scalable business process, which may result in new business methods for therapist placement

Support feature parity and quality assurance across AlchemistOne's iOS and Android platforms for their AI-assisted therapy tools enhancing delivery speed and product stability.

The project will be co-developed with international partners and adapted for applications in education, training, and workforce development, with strong commercialization potential across multiple service industries such as personal training, mental health therapy, social work, coaching, etc.

As part of the international consortium project “NPmsDNA2024: Development of in vivo targeted non-viral gene therapies” this project will focus on leveraging Entos’ Fusogenix PLV formulations optimized for delivery of DNA-based genetic medicines to target cell types of the retina to address unmet medical need in rare ophthalmological diseases, including Stargardt Disease.

It is also necessary to provide a better description of the molecular mechanisms by assessing how blood clotting genes are differentially expressed under microgravity. To this end, the proposed research will 1) identify jugular vein status and coagulation changes in spaceflight analogue of dry immersion and bed rest by analysis of blood samples, and 2) investigate the molecular mechanisms that underlie the risk of VTEs by assessing the genes associated with coagulation. The outcome of this project would be a better understanding of the potential underlying mechanisms of VTEs in spaceflight.